Project Grant HT94252510184
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The Department of the Army Medical Command awarded a $693,513 Project Grant to Brigham & Women's Hospital Inc. through the Military Medical Research and Development program. The grant will fund research into the molecular mechanisms of therapy-related myeloid neoplasms from September 30, 2022 to September 29, 2025. As the stated purpose of the Military Medical Research and Development program is to transform military and public health through innovative medical research solutions, this award...
This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
This $168,042 Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research conducted by Brigham & Women's Hospital Inc. to investigate in-vivo targeting of TFE3 dimerization partners in translocation renal cell carcinoma. The research project aims to develop novel diagnostic technologies and advance the understanding of complex medical conditions related to this form of kidney cancer. The awardee,...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The Department of the Army Medical Command awarded a $1,416,000 project grant to Boston Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to define leukemia stem cells in acute lymphoblastic leukemia from September 2021 through September 2025. Through this funding, Boston Children's Hospital researchers will investigate medical solutions for the battlefield by transforming healthcare for service members and the public. The...
The Defense Health Agency awarded a $522,477 Project Grant to Boston Medical Center Corporation (BMC) under the Military Medical Research and Development program (CFDA 12.420). The funding will support research to define genetic vulnerabilities in pancreatic neuroendocrine tumors that rely on the alternative lengthening of telomeres pathway. This 3-year project grant runs from August 1, 2023 to July 31, 2026. A sub-award of an unspecified amount was provided to the Trustees of Boston...
This Project Grant award for $1,789,999.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program, supports a novel approach to increase fetal and embryonic hemoglobins for the treatment of sickle cell anemia. The award recipient, Brigham & Women's Hospital Inc., a prominent academic medical center in Boston, Massachusetts, will conduct this research over a 3-year period from Mar 1, 2025 to Feb 29, 2028. The grant...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $819,980.00 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on elucidating sex differences in melanoma tumorigenesis. The 3-year research project, beginning on August 15, 2024 and ending on August 14, 2027, aims to advance the understanding and treatment of this complex...
The Department of the Army Medical Command awarded a $1,419,356 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2025 to develop novel immunotherapy approaches to suppress cancer metastasis and recurrence in bone. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...